Serum Leptin Levels in Women with Immunological Recurrent Abortion

Zarei, Saeed (M.D.)1; Soltanghoraei, Haleh (M.D.)2; Mohammadzadeh, Afsaneh (M.D.)2; Arefi, Soheila (M.D.)2; Zarnani, Amir Hassan (Ph.D.)2; Idali, Farah (Ph.D.)2; Tavangar, Banafsheh (B.Sc.)1; Savadi Shiraz, Elham (M.Sc.)2; Moshef Behzad, Narges (B.Sc.)2; Jeddi-Tehrani, Mahmood (Ph.D.)1*

1- Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
2- Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
3- Nanotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran

Abstract

Introduction: Recurrent abortion (RA) may be a consequence of aberrant expression of immunological factors during pregnancy. Although the relative importance of immunological factors in human reproduction remains controversial, substantial evidence suggests that autoantibodies contribute to reproductive failure. Production of such antibodies is under the control of cytokines; and leptin, besides its role in reproductive success, has a profound effect on directing the cytokine profile toward Th1 (cellular) pattern. Therefore, the present study was performed to assess serum leptin levels in women with immunological recurrent abortion.

Materials and Methods: In this prospective study, 250 women who attended Avicenna Infertility Clinic with RA were screened for known causes of abortion from July to December 2008 in Tehran, Iran. Eighty-one patients with normal karyotypes and hormonal profile with normal ovaries and uterus and no signs of infection were categorized as patients with immunological (IRA, n = 39) or unexplained (URA, n = 42) recurrent abortion based on presence or absence of autoantibodies. After blood sampling, levels of anti-nuclear antibody (ANA), anti-double stranded DNA antibody (anti-dsDNA), lupus anti-coagulant antibody (LACAb), anti-phospholipid antibody (APA), anti-cardiolipin antibody (ACA), anti-thyroglobulin antibody (TgAb), anti-thyroperoxidase antibody (TPOAb) and anti-thrombin III antibody (ATIIIAb) were measured by enzyme-linked immunosorbent assay (ELISA) or chemiluminescent enzyme immunoassay (CLEIA).

Results: In IRA group, 9 (23.1%), 24 (61.5%), 25 (64.1%) and 1 (2.6%) women were above the normal cut-off point for ANA, TgAbs, TPOAbs and AT-III Abs, respectively. IRA patients had normal values of LACAbs, APA and ACA. With normal level of fasting blood sugar (FBS), IRA and URA groups had similar serum leptin levels (23.7 ± 13.2 ng/ml vs. 22.7 ± 12.5 ng/ml, respectively). Serum leptin concentrations showed a positive correlation with weight and BMI in both groups.

Conclusion: This study suggests that serum leptin levels are higher in IRA and URA patients than normal women. The findings of this study suggest the need for a more comprehensive study and comparison of leptin levels in IRA and URA patients to women with no history of miscarriages.

Keywords: Autoantibodies, Immunological, Leptin, Pregnancy, Recurrent abortion, Spontaneous abortion.

To cite this article: Zarei S, Soltanghoraei H, Mohammadzadeh A, Arefi S, Zarnani AH, Idali F, et al. Serum Leptin Levels in Women with Immunological Recurrent Abortion. J Reprod Infertil. 2010;11(1):47-52.

Introduction: Recurrent abortion (RA) is a growing problem all over the world (1). RA occurs in both natural and in-vitro fertilization (IVF)-mediated pregnancies, and there is increasing evidence that...
immunological factors play an important role in the failure of these pregnancies (2-4). These factors include various humoral abnormalities such as anti-nuclear antibodies (ANA), anti-double stranded DNA antibodies (anti-dsDNA), lupus anti-coagulant (LACAb), anti-phospholipid (APA), anti-cardiolipin (ACA), anti-thyroglobulin (TgAb), anti-thyroid peroxidase (TPOAb) and anti-thrombin III antibodies (ATIIIAb). The association of recurrent losses of natural or artificial pregnancies with immunological abnormalities has been termed as immunological recurrent abortion (IRA) when other factors such as anatomical abnormalities, endocrine disorders and abnormal karyotypes have been ruled out (5).

It has been reported that presence of some types of autoantibodies are associated with Th1 cytokine profile; which among them are ANA in patients with Sjögren's syndrome (6), rheumatic diseases (7) and multiple sclerosis (8), anti-dsDNA in NZB/W F1 lupus-prone mice (9), APA in recurrent spontaneous abortions (10), TgAbs in Graves' disease (11), TPOAbs in Hashimoto's thyroiditis (12) and thyroid-associated ophthalmopathy (13) and AT-III Abs in spontaneous abortion (14).

Leptin, a 167-amino acid polypeptide, is secreted mainly by adipocytes. It is involved in signaling the amount of body fat to hypothalamic nuclei, leading to body weight homeostasis (15). Leptin is thought to regulate reproductive functions, as ob/ob mutant mice which lack leptin are infertile and administration of recombinant leptin to these animals corrects the reproductive defect (16).

During gestation, leptin is produced and secreted by trophoblastic cells (17) and its maternal serum levels increase progressively, reaching a peak during the second trimester and remain relatively constant thereafter (18). There is a prompt fall in its concentration after parturition, indicating that placental leptin may represent a significant source of maternal leptin (19).

In addition to its critical involvement in physiological functions, leptin has been increasingly recognized as a cytokine-like hormone with pleiotropic actions in modulating immune responses (20). Moreover, leptin can activate and stimulate monocytes, dendritic cells (DC) and macrophages to produce Th1 type cytokines (21). Importantly, leptin has been shown to modulate the adaptive immunity via enhancing T cell survival and stimulating their production of pro-inflammatory cytokines such as IFN-γ and IL-2 (22).

All the studies reported so far, have mainly focused on the role of leptin and abortion during the course of pregnancy and / or abortion (23-28). However, the present study aims at studying the role of leptin in women with RA beyond pregnancy.

Considering the profound effects of leptin on immune system functions, the present study was undertaken to investigate the serum levels of leptin in women with immunological recurrent abortions.

**Materials and Methods**

**Patients:** The study population comprised of women with a history of two or more miscarriages during natural or IVF-mediated pregnancies. Anatomic, infectious, genetic and hormonal causes for RA were excluded. Among 250 women with RA who attended Avicenna Infertility Clinic in Tehran, Iran, 81 patients who had normal karyotypes and hormonal profile and did not have anatomical abnormalities in the reproductive organs or any signs of infectious diseases were categorized as patients with immunological (IRA, n = 39) or unexplained (URA, n = 42) causes of recurrent abortion. The patients were screened by a battery of immunological tests including ANA, anti-dsDNA, LACAb, APA, ACA, TgAb, TPOAbs and AT-III Abs and cases with one or more positive results for these autoantibodies were categorized as the IRA group. Women with negative findings for the aforesaid autoantibodies were grouped as URA cases.

**Study design:** This prospective study was conducted in Avicenna Infertility Clinic in Tehran, Iran from July to December 2008. When patients signed a written informed consent, blood samples were obtained and the sera were stored at -20°C. The levels of leptin and autoantibodies were measured by enzyme-linked immunosorbent assay (ELISA) or chemiluminescence enzyme immunoassay (CLEIA) methods.

The study protocol was approved by Avicenna Research Institute’s Ethics Committee and it was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.
Serological Evaluations: Serum levels of leptin and autoantibodies were measured by ELISA and CLEIA methods according to the manufacturer's instructions. Kits used in this study were purchased from the following companies: Leptin ELISA (BioVendor, Czech Republic), APA and ACA ELISA (Orgentech Diagnostica GmbH, Mainz, Germany), ANA and anti-dsDNA ELISA (Aesku Diagnostics, Wendelsheim, Germany), TgAbs and TPOAbs CLEIA (DiaSorin, Antony, France), AT-III Abs, and LACAbs CLEIA (Diagnostica Stago, Asnieres, France).

Minimal detection levels of commercial kits for Leptin, anti-dsDNA, LACAbs, APA, ACA, TgAbs, TPOAbs and AT-III Abs were 0.17 ng/ml, 1 U/ml, 3 sec, 0.5 IU/ml, 1 IU/ml, 0.8 IU/mL, 6 IU/mL and 9% activity, respectively.

Statistical Analyses: Two-tailed statistical analyses were performed using SPSS software, version 13 (SPSS Inc., Chicago, Illinois, U.S.A.). The proportion of women with antibodies above the defined threshold, as suggested by the ELISA and CLEIA kits manufacturers, were computed and the Spearman rank correlation coefficient was employed to investigate the correlation of the variables. Differences among groups in variables were determined by using the Mann–Whitney U test. P-values less than 0.05 were considered statistically significant.

Results

Study Population: In this study, 39 (48%) patient had abnormal results for one or more immunoologic tests (IRA group). However, URA group consisted of 42 (52%) women with normal results for autoantibodies. All the patients were compared in terms of height, weight, BMI (body mass index), FBS (fasting blood sugar) and age with no significant differences being found between the two groups (Table 1).

Serum levels of leptin and autoantibodies: All 39 women with IRA had normal values of anti-dsDNA (cut-off point >16 U/ml), LACAbs (cut-off point >50 seconds), APA (cut-off point >10 IU/ml) and ACA (cut-off point >10 IU/ml), but one case (2.6%) showed an increased level of AT-

| Variables                          | Immunologic recurrent abortion | Unexplained recurrent abortion | P-value* | Normal range |
|------------------------------------|--------------------------------|--------------------------------|----------|--------------|
| Age (year)                         | M ± SD                          | M ± SD                          | P-value* | Normal range |
| Weight (Kg)                        | 32 ± 6                          | 31 ± 6                          | 0.44     | ND           |
| Height (m)                         | 62 ± 9                          | 63 ± 6                          | 0.51     | ND           |
| Body mass index (Kg/m²)            | 1.61 ± 0.05                     | 1.59 ± 0.05                     | 0.16     | ND           |
| Anti-nuclear antibodies (U/ml)     | 1.18 ± 3.83                     | 0.25 ± 0.21                     | 0.007    | < 0.8        |
| anti-double stranded DNA antibodies (U/ml) | 2.5 ± 5.1              | 3.3 ± 6.3                       | 0.71     | < 16         |
| Lupus anti-coagulant antibodies (Second) | 37.5 ± 5.2                      | 37.8 ± 4.3                      | 0.58     | 30-50        |
| Anti-phospholipid antibodies (IU/ml) | 3.8 ± 2.0                        | 3.9 ± 2.0                        | 0.86     | < 10         |
| Anti-cardiolipin antibodies (IU/ml) | 3.2 ± 2.2                        | 3.1 ± 2.3                        | 0.69     | < 10         |
| Anti-thyroglobulin antibodies (IU/ml) | 234 ± 290                      | 13.6 ± 13.3                     | < 0.001  | 5-100        |
| Anti-thyroperoxidase antibodies (IU/ml) | 140 ± 210                       | 2.6 ± 2.8                       | < 0.001  | 1-16         |
| Anti-trombin III (% Activity)      | 94 ± 10                         | 95 ± 11                         | 0.64     | 80-100       |
| FBS (mg/dL)                        | 85 ± 7                          | 83 ± 8                          | 0.90     | 70-105       |
| Leptin (ng/ml)                     | 23.7 ± 13.2                     | 22.7 ± 12.5                     | 0.75     | ND           |

ND: Not defined, * Mann–Whitney U test

Table 1. Summary of demographic and clinical characteristics of the women with immunologic recurrent abortion
III Abs (cut-off point >120% activity). Nine women (23.1%) had antibody levels above the defined threshold for ANA (cut-off point >1.2 U/ml), 24(61.5%) for TgAbs and 25 (64.1%) for TPOAbs.

Since serum levels of leptin is highly dependent on serum sugar concentration (29), fasting blood sugar (FBS) was first measured in all women and it was shown to be within normal ranges in IRA (mean 85 ± 7 mg/dL) and URA (Mean 83 ± 8 mg/dL) cases. Serum levels of leptin were higher in 31(79.5%) (Mean 23.7 ± 13.2 ng/ml) IRA and 33 (78.6%) (mean 22.7 ± 12.5 ng/ml) URA patients relative to the considered cut-off point. At the present time there is no valid cut-off point for serum leptin levels for the Iranian population, therefore a cut-off point which had been reported by Nystrom et al was employed (30). Currently, no international cut-off point for serum leptin levels has been defined yet. Serum leptin concentration showed positive correlations with weight \( r = 0.613, p = 0.001 \) and BMI \( r = 0.621, p = 0.001 \) in IRA, as it did in URA patients, respectively \( r = 0.565, p < 0.001 \) and \( r = 0.554, p < 0.001 \).

**Discussion**

Various immunological abnormalities that interfere with a successful pregnancy (31) have been identified. A considerable portion of immunological abnormalities appear to be caused by a shift in the immune response away from the so called Th₂ (humoral) pattern toward the so called Th₁ (cellular) profile that is deleterious to pregnancy outcomes (31). Likewise, leptin has been shown to have a profound effect on reproduction. Leptin deficient homozygote ob mice remain in a prepubertal stage despite a normal early sexual differentiation (32). These findings further support the idea that leptin is possibly involved in the control of fertility, but a definitive proof was obtained when it was shown that administration of leptin could restore fertility in ob / ob mice (16, 33, 34) by allowing them to achieve pubertal maturity.

Lage and colleagues conducted the first study on the role of leptin in spontaneous abortion in 1999 (23). In that study, serum leptin levels were measured in 29 women with spontaneous abortion, 24 hours after the incident and showed lower leptin levels in RA patients compared to normal women (23). In another study by Laird and collages measured serum leptin levels in 53 women with a history of RA at 5-6th and 6-8th weeks into gestation. They also reported lower leptin levels in RA patient who underwent miscarriage in the aforementioned intervals than those who managed to continue their pregnancies to full term (26). Interestingly, anti-progesterone medications (Mifepristone) has been shown to significantly decrease serum leptin levels leading to abortion two days after the drug administration in candidates for induced abortion (25). However, the existing information on the effects of serum leptin on pregnancy outcome is controversial as evidenced in the study by Thommaselli and colleagues. They showed similar leptin levels in the first trimester of women who had normal full term deliveries as compared to those who aborted the course of pregnancy in the first trimester (28).

To our knowledge, it seems that no study has been carried out on the effects of serum leptin levels on pregnancy outcome in women with RA in periods well beyond the pregnancy period and the present study maybe the first to serve this aim. In addition, the existing data is lacking regarding the effects of leptin levels on specified groups of RA patients. The present study is also is aiming at analyzing serum leptin levels in women with IRA. Leptin is a well-defined agent that can enhance Th₁ immunity (21). Since Th₂ cytokine profile is dominant during most of gestational period and Th₁ cytokines are reportedly incompatible with successful pregnancy, we hypothesized that overproduction of leptin in women with RSA may lead to the production of Th₁-associated autoantibodies and indirectly trigger fetal loss. Based on the fact that, serum leptin concentration is profoundly dependent on FBS levels (29), the latter was measured in all patients and it was found to be within normal ranges. No significant differences in serum leptin levels were found between IRA and URA groups. In line with our findings, it has recently been reported that serum leptin levels in the first trimester of pregnancy may not be the primary indicator of miscarriage in cases of threatened abortion (28). In women with a history of recurrent miscarriage the same conclusion has been outlined (26). Importantly, a significant correlation between
BMI and serum leptin levels was found in the experimental groups which is in line with what Nystrom et al have reported (30).

**Conclusion**

This study suggests that serum leptin levels are higher in IRA and URA patients compare to those of normal women. It seems that separating known causes of recurrent abortion (genetic, infectious, anatomical and hormonal) from immunological causes is necessary to have a better understanding about mechanisms leading to miscarriage.

Lack of a statistically significant difference between serum leptin levels in RA and URA patients might be due to the low number of samples in each group, therefore, a more comprehensive study is suggested for comparing serum leptin levels in IRA and URA patients with those in normal women without a history of miscarriage.

**Acknowledgement**

The authors are grateful to the individuals who accepted to participate in this study. We are indebted to the personnel of Avicenna Infertility Clinic for their assistance in sample collection. This work was supported by a grant from Iranian Academic Center for Education, Culture and Research (ACECR).

**References**

1. Cramer DW, Wise LA. The epidemiology of recurrent pregnancy loss. Semin Reprod Med. 2000;18 (4):331-9.
2. Gleicher N, Friberg J. IgM gammopathy and the lupus anticoagulant syndrome in habitual aborters. JAMA. 1985;253(22):3278-81.
3. Xu L, Chang V, Murphy A, Rock JA, Damewood M, Schlaff W, et al. Antinuclear antibodies in sera of patients with recurrent pregnancy wastage. Am J Obstet Gynecol. 1990;163(S Pt 1):1493-7.
4. Stagnaro-Green A, Roman SH, Cobin RH, El-Harazy E, Alvarez-Marfany M, Davies TF. Detection of at-risk pregnancy by means of highly sensitive assays for thyroid autoantibodies. JAMA. 1990;264(11):1422-5.
5. Stricker RB, Winger EE. Update on treatment of immunologic abortion with low-dose intravenous immunoglobulin. Am J Reprod Immunol. 2005;54 (6):390-6.
6. He J, Wang H, Zhao JX, Li ZG. [Establishment of Sjogren's syndrome models by immunization with alpha-Fodrin: experiment with mice]. Zhonghua Yi Xue Za Zhi. 2008;88(33):2360-3. Chinese.
7. Mosaad YM, Metwally SS, AUF FA, AbdEl-Samee ER, el-Deek B, Limon NI, et al. Proinflammatory cytokines (IL-12 and IL-18) in immune rheumatic diseases: relation with disease activity and auto-antibodies production. Egypt J Immunol. 2003;10 (2):19-26.
8. Spadaro M, Amendolea MA, Mazzuccconi MG, Fantozzi R, Di Lello R, Zangari P, et al. Autoimmunity in multiple sclerosis: study of a wide spectrum of autoantibodies. Mult Scler. 1999;5(2): 121-5.
9. Enghard P, Langnickel D, Riemekasten G. T cell cytokine imbalance towards production of IFN-gamma and IL-10 in NZB/W F1 lupus-prone mice is associated with autoantibody levels and nephritis. Scand J Rheumatol. 2006;35(3):209-16.
10. Graphou O, Chioti A, Pantazi A, Tsukoura C, Kontopoulos V, Guergiadou E, et al. Effect of intravenous immunoglobulin treatment on the Th1/Th2 balance in women with recurrent spontaneous abortions. Am J Reprod Immunol. 2003;49 (1):21-9.
11. Zhang JA, Zhang J, Xu L, Mar H, Wu XY. [Measurement of IL-12 and IL-18 in sera of patients with autoimmune thyroid disease]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2006;22(5):630-2. Chinese.
12. Gérard AC, Boucquey M, van den Hove MF, Colin IM. Expression of TPO and ThOxs in human thyrocytes is downregulated by IL-1alpha/IFN-gamma, an effect partially mediated by nitric oxide. Am J Physiol Endocrinol Metab. 2006;291 (2):E242-53.
13. Förster G, Otto E, Hansen C, Ochs K, Kahaly G. Analysis of orbital T cells in thyroid-associated ophthalmopathy. Clin Exp Immunol. 1998;112(3): 427-34.
14. Clark DA, Ding JW, Chaouat G, Coulam CB, August C, Levy GA. The emerging role of immunoregulation of fibrinogen-related procoagulant Fgl2 in the success or spontaneous abortion of early pregnancy in mice and humans. Am J Reprod Immunol. 1999;42(1):37-43.
15. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature.1994;372(6505):425-32.
Serum leptin levels in immunological Recurrent Abortion

16. Chehab FF, Lim ME, Lu R. Correction of the sterility defect in homozygous obese female mice by treatment with the human recombinant leptin. Nat Genet. 1996;12(3):318-20.

17. Masuzaki H, Ogawa Y, Issa N, Satoh N, Okazaki T, Shigemoto M, et al. Human obese gene expression. Adipocyte-specific expression and regional differences in the adipose tissue. Diabetes. 1995;44(7):855-8.

18. Schubring C, Kiess W, Englaro P, Rascher W, Dötsch J, Hanitsch S, et al. Levels of leptin in maternal serum, amniotic fluid, and arterial and venous cord blood: relation to neonatal and placental weight. J Clin Endocrinol Metab. 1997;82(5):1480-3.

19. Malik NM, Carter ND, Wilson CA, Scaramuzzi RJ, Stock MJ, Murray JF. Leptin expression in the fetus and placenta during mouse pregnancy. Placenta. 2005;26(1):47-52.

20. Lord GM, Matarese G, Howard JK, Baker RJ, Bloom SR, Lechler RI. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature. 1998;394(6696):897-901.

21. Mattioli B, Straface E, Quaranta MG, Giordani L, Viora M. Leptin promotes differentiation and survival of human dendritic cells and licenses them for Th1 priming. J Immunol. 2005;174(11):6820-8.

22. Loffreda S, Yang SQ, Lin HZ, Karp CL, Brengman ML, Wang DJ, et al. Leptin regulates proinflammatory immune responses. FASEB J. 1998;12(1):57-65.

23. Lage M, Garcia-Mayor RV, Tomé MA, Cordido F, Valle-Inclán F, Considine RV, et al. Serum leptin levels in women throughout pregnancy and the postpartum period and in women suffering spontaneous abortion. Clin Endocrinol (Oxf). 1999;50(2):211-6.

24. Choi HK, Choi BC, Lee SH, Kim JW, Cha KY, Baek KH. Expression of angiogenesis- and apoptosis-related genes in chorionic villi derived from recurrent pregnancy loss patients. Mol Reprod Dev. 2003;66(1):24-31.

25. Honkanen H, Ranta S, Ylikorkala O, Heikinheimo O. Effect of antiprogestosterone mifepristone followed by misoprostol on circulating leptin in early pregnancy. Acta Obstet Gynecol Scand. 2005;84(2):134-9.

26. Laird SM, Quinton ND, Anstie B, Li TC, Blakemore AI. Leptin and leptin-binding activity in women with recurrent miscarriage: correlation with pregnancy outcome. Hum Reprod. 2001;16(9):2008-13.

27. Makrydimas G, Vandecruys H, Sotiriadis A, Lakasing L, Spencer K, Nicolaides KH. Coelomic fluid leptin concentration in normal first-trimester pregnancies and missed miscarriages. Fetal Diagn Ther. 2005;20(5):406-9.

28. Tommaselli GA, Di Spiezie Sardo A, Di Carlo C, Bifulco G, Cerrota G, Cirillo D, et al. Do serum leptin levels have a role in the prediction of pregnancy outcome in case of threatened miscarriage? Clin Endocrinol (Oxf). 2006;65(6):772-5.

29. Morton GJ. Hypothalamic leptin regulation of energy homeostasis and glucose metabolism. J Physiol. 2007;583(Pt 2):437-43.

30. Nyström F, Ekman B, Osterlund M, Lindström T, Ohman KP, Arness HJ. Serum leptin concentrations in a normal population and in GH deficiency: negative correlation with testosterone in men and effects of GH treatment. Clin Endocrinol (Oxf). 1997;47(2):191-8.

31. Piccinni MP, Beloni L, Livi C, Maggi E, Scarselli G, Romagnani S. Defective production of both leukemia inhibitory factor and type 2 T-helper cytokines by decidual T cells in unexplained recurrent abortions. Nat Med. 1998;4(9):1020-4.

32. Barkan D, Hurvin V, Dekel N, Amsterdam A, Rubinstein M. Leptin induces ovulation in GnRH-deficient mice. FASEB J. 2005;19(1):133-5.

33. Barash IA, Cheung CC, Weigle DS, Ren H, Kabigtine EB, Kuijper JL, et al. Leptin is a metabolic signal to the reproductive system. Endocrinology. 1996;137(7):3144-7.

34. Mounzih K, Lu R, Chehab FF. Leptin treatment rescues the sterility of genetically obese ob/ob males. Endocrinology. 1997;138(3):1190-3.